AMIX Autonomix Medical, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1617867 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $1.58M | $1.51M | $1.46M | $1.72M | $2.37M | $1.59M | $1.55M | $1.04M |
| SG&A expense | $1.59M | $1.25M | $1.28M | $1.62M | $5.17M | $1.83M | $1.70M | $1.70M |
| Operating income | -$3.18M | -$2.77M | -$2.74M | -$3.34M | -$7.53M | -$3.42M | -$3.25M | -$2.75M |
| Interest expense | — | — | $0 | $0 | $0 | $0 | $46,000 | $45,000 |
| Pretax income | -$3.13M | -$2.73M | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.19M | -$2.71M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.13M | -$2.73M | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.19M | -$2.71M |
| EBITDA | -$3.17M | -$2.77M | -$2.73M | -$3.34M | -$7.53M | -$3.42M | -$3.20M | -$2.70M |
| EPS (basic) | -2.51 | -5.02 | — | -0.36 | -29.02 | -22.69 | — | -1.46 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.69M | $3.46M | $7.00M | $9.93M | $7.48M | $8.59M | $9.14M | $11.82M |
| Current assets | $8.18M | $3.96M | $7.58M | $10.19M | $7.89M | $8.98M | $9.61M | $11.93M |
| PP&E, net | $19,000 | $16,000 | $19,000 | $20,000 | $16,000 | $19,000 | $21,000 | $20,000 |
| Total assets | $8.20M | $3.98M | $7.60M | $10.21M | $7.93M | $9.00M | $9.81M | $11.95M |
| Current liabilities | $1.25M | $818,000 | $1.71M | $1.65M | $1.49M | $1.97M | $1.71M | $2.25M |
| Short-term debt | — | — | — | — | — | — | — | $1.13M |
| Total liabilities | $1.25M | $818,000 | $1.71M | $1.65M | $1.49M | $1.97M | $1.71M | $2.25M |
| Shareholders' equity | $6.94M | $3.16M | $5.89M | $8.56M | $6.45M | $7.03M | $8.10M | $9.71M |
| Shares outstanding | 1.96M | 542,312 | 542,312 | 11.41M | 6.19M | 4.02M | 2.50M | 2.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.61M | -$3.54M | -$2.89M | -$2.97M | -$3.82M | -$2.60M | -$2.55M | -$2.30M |
| Capital expenditure | — | — | $3,000 | $7,000 | $0 | $0 | $4,000 | $5,000 |
| Free cash flow | — | — | -$2.90M | -$2.98M | -$3.82M | -$2.60M | -$2.56M | -$2.31M |
| Investing cash flow | — | — | -$3,000 | -$7,000 | $0 | $0 | -$4,000 | -$5,000 |
| Financing cash flow | $6.85M | $0 | -$35,000 | $5.43M | $2.71M | $2.06M | -$174,000 | $8.97M |
| Depreciation & amortization | $4,000 | $3,000 | $3,000 | $4,000 | $2,000 | $3,000 | $48,000 | $47,000 |
| Stock-based compensation | $53,000 | $2,000 | $1,000 | $2,000 | $138,000 | $388,000 | $405,000 | $418,000 |
Free plan shows the latest 8 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.